High Purity New England

Industrial Impact

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Industrial Impact

Dewpoint Therapeutics | August 18, 2022

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

PR Newswire | May 11, 2020

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...